The composition of the gut microbiome appears to be associated with treatment response in patients with pancreatic cancer, research suggests.

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer and presents a 5-year survival rate of less than 10%. Novel therapies focusing on targeting the tumor ...

Citation: Zhang D, Jiang Z, Hu J, Sun X, Zheng Y and Shen Y (2023) Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in ...

Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have prolonged OS. Pancreatic ...

Revolution Medicines' daraxonrasib receives FDA Breakthrough Therapy Designation for treating metastatic pancreatic cancer with specific KRAS mutations.

Genomic profiling of ampullary adenocarcinoma (AA): Insights from a comparative analysis of pancreatic and intestinal adenocarcinoma and opportunities for targeted therapies use.

The FDA has granted fast track designation to nadunolimab for use in combination with gemcitabine and nab-paclitaxel to treat patients with previously untreated, metastatic PDAC with high IL1RAP ...